ProCE Banner Activity

ATLAS: Week 48 Results From Phase III Study of Switching to Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Patients With No Prior Virologic Failure

Slideset Download
Conference Coverage
Switch to long-acting dual therapy regimen maintains virologic suppression at Week 48.

Released: March 09, 2019

Expiration: March 07, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This program is supported by independent educational grants from

Gilead

Gilead Text

Janssen

Merck Human Health HIV

ViiV Healthcare